TGTX · TG Therapeutics, Inc.

The thesis

TG Therapeutics' case rests on BRIUMVI, its multiple-sclerosis drug, and the third-quarter report expected around 3 November 2026 decides whether sales growth continues. The company reported second-quarter 2026 US BRIUMVI net revenue of $227.7 million, about 64% above the year-earlier quarter, and on 3 August 2026 raised its full-year US BRIUMVI target to $890–905 million (company results).

The narrative is maturing: the sales story is well known, and the two newest items are clinical-data releases, not operating results. On 12 October 2026 the company published a five-year indirect comparison of BRIUMVI against ocrelizumab and ofatumumab, and on 21 October 2026 it presented further data at MSToronto2026. The shares closed at $53.16 on 22 October 2026, 10.0% below the $59.06 52-week high. The rating stays low because neither release changes the revenue path that the next report tests.

Bullish and bearish views on TG Therapeutics, Inc.

The bull case on TG Therapeutics, Inc. (TGTX), in brief: Sales growth has a reported benchmark. The bear case: Revenue is concentrated in one product.

Bull case

• Sales growth has a reported benchmark. The company said second-quarter US BRIUMVI net revenue rose 17% from the first quarter and more than 64% from a year earlier.
• Total revenue guidance was raised. The 3 August 2026 release lifted full-year 2026 global revenue guidance to about $950 million. Second-quarter global revenue was $240.3 million, of which US BRIUMVI was $227.7 million.
• A new comparative data set supports the marketing case. On 12 October 2026 the company said BRIUMVI showed a 44% lower risk of disability progression than ocrelizumab and 49% lower than ofatumumab in a five-year matching-adjusted indirect comparison. The paper reports 24-week confirmed disability progression at 240 weeks of 9.3% versus 16.1% for ocrelizumab and 9.4% versus 17.9% for ofatumumab.
• Simpler dosing cleared a clinical test. The company reported on 27 May 2026 that Phase 3 ENHANCE met its exposure-equivalence endpoint for a consolidated initial BRIUMVI infusion regimen. A regulatory submission is the next step; approval is not established.
• Analysts remain constructive. Analyst-ratings aggregators list HC Wainwright reiterating a Buy with a $78 price target on 1 September 2026, and JPMorgan raising its target to $72 on 7 August 2026.

Bear case

• Revenue is concentrated in one product. US BRIUMVI was $227.7 million of $240.3 million total global revenue in the second quarter of 2026. A third-quarter US figure below $227.7 million would break the growth story.
• The comparison is model-based. The 12 October 2026 analysis is an unanchored indirect comparison, not a randomized head-to-head trial. Independent coverage notes it is described by its authors as exploratory and was funded by the drug's European commercialisation partner; results were not lower in every year, with Year 3 relapse rates at 0.054 for BRIUMVI and 0.053 for ofatumumab.
• Spending is rising alongside sales. The 3 August 2026 results guided full-year operating expenses of $350–400 million, excluding non-cash compensation. The company also flagged about $100 million of subcutaneous BRIUMVI manufacturing and secondary-manufacturer start-up costs.
• The subcutaneous readout has no exact date. Phase 3 topline is guided to year-end 2026 or the first quarter of 2027. A miss on the prespecified exposure non-inferiority endpoint would weaken the dosing-convenience argument.
• Pipeline expansion rests on small samples. The 9 June 2026 myasthenia gravis Phase 1 topline covered 11 participants, which is too small a sample to support an efficacy conclusion.

Price setup

Adjusted daily closes show $55.37 on 9 October 2026 and $53.16 on 22 October 2026. The 14-day relative strength index (RSI) was 45.7 on 22 October 2026, against 79.8 reported by Benzinga on 15 June 2026 when the shares were overbought. The three-month price change was -4.6%.

The $59.06 52-week high is the upside reference; a weekly close above it would be a new high. The $46 level marks the June breakout retest, and a weekly close below it would return the shares to the pre-breakout range. The shares have drifted lower while two clinical-data releases passed without lifting them.

Crowding evidence is limited. The most recent heavy retail and options attention in company news dates from June (Benzinga, 15 June 2026 and 1 July 2026). No SEC filings were reported in the latest check, so insider selling or share issuance cannot be observed. The earnings date sits about two weeks out.

Catalysts, next 30 days

• ~31 December 2026, est.: Subcutaneous BRIUMVI Phase 3 topline, guided to year-end 2026 or the first quarter of 2027. It falls outside the 30-day window but is the next large clinical event.

Elapsed catalysts

• ~30 October to 3 November 2026, est.: The company has not yet announced its third-quarter call. Last year it announced on 31 October 2025 for a call on 3 November 2025, and this year's second-quarter call was held on 3 August 2026. (passed 3d ago)
• ~3 November 2026, est.: Third-quarter 2026 results and business update. This tests US BRIUMVI net revenue against the $227.7 million second-quarter level and the $890–905 million full-year US guide. (passed 3d ago)

What would change the view

The case breaks if third-quarter 2026 US BRIUMVI net revenue prints below the $227.7 million second-quarter level, or if the $890–905 million US guide is cut. A Phase 3 miss on the subcutaneous exposure endpoint would also weaken it. On price, a weekly close below $46, the June breakout retest, would return the shares to the pre-breakout range.

The case strengthens if third-quarter revenue clears $227.7 million with the full-year guide held or raised, which would show the run-rate path to about $1 billion is intact. A weekly close above the $59.06 high would show buyers returning.

What it trades with

TGTX trades on its own sales and clinical news more than on sector moves. Its June rally coincided with a broad set of health-care and growth gainers (Benzzinga, 10 June 2026), but no current theme cluster carries the name. BRIUMVI competes with Roche's Ocrevus and Novartis's Kesimpta, so competitor data, pricing or label changes in anti-CD20 multiple-sclerosis therapy are the most direct outside influence on the shares.